To the implementation of the medical network on March 8 - two votes, against the background of integration is refers to the trend of The Times in the field of pharmaceutical business. Below market expectations, however, is that as the policy of gradually fall to the ground, medicine and the integration of large-scale did not appear in the commercial sector.
"In the field of pharmaceutical commercial enterprises there are many callings, a ticket, falsely making out invoice is qualitative as violation of historical existence, thus lead to integrate business enterprise may carry on fiscal risk." Third party medical service platform MaiSiKang Shi Lichen founder said, now the stagnation of the basic medical business integration.
Drug firms seeking sales model transformation
Analysts believe that the "two votes" the compressed pharmaceutical circulation, medicine circulation industry will be further integrated, comprehensive competitiveness strong large pharmaceutical circulation enterprises have obvious benefit.
Shi Lichen said, at present, there are thousands of pharmaceutical enterprises in China, but there are not many pharmaceutical companies have proprietary team. Most companies still is given priority to with the proxy pattern. Policies such as two votes away, pharmaceutical enterprise marketing without any proprietary team will fall into a state of unsustainable.
In the face of two votes, some medical production enterprises select cooperation with large pharmaceutical commercial enterprises.
Wide raw hall in February issued "about with sinopharm co., LTD. Signed a strategic cooperation agreement in the announcement, cooperation include: wide raw hall to its holdings give priority to the production of pharmaceutical products are in conformity with national quality standard, entrust its owned subsidiary belongs to regional distribution or agent for the sale, and makes the sinopharm affiliated subsidiaries become wide hall dealers; Wide raw hall with the help of sinopharm the sound distribution network and logistics platform, give priority to ensure that direct hospital, retail terminal or via a commercial distribution to reach sales terminals, thereby reducing marketing links and reduce costs, ensure smooth sales; And so on.
Wide raw hall, said the signing of this agreement is the company's positive response to the drug circulation "two votes", promote sales model is an important step in the transformation and upgrading, is both sides further sharing resources, reduce costs, improve efficiency, enhance the risk resistance ability of the enterprise of a win-win situation. The signing of this agreement will straighten out the company's drug delivery system, enlarge the coverage of the company's products terminal, is expected to 2017 annual business performance has a positive influence to the company.
Compliance issues hinder the mergers and acquisitions
Some analysts believe that after the "two votes" push, number of pharmaceutical commercial enterprises will decrease sharply, a large number of small and medium-sized enterprises will be mergers and acquisitions, leading pharmaceutical commercial enterprises will benefit. However, this phenomenon for compliance problems did not appear large-scale enterprises.
Shi Lichen said, there are 46 because commercial enterprises affiliated, tickets, falsely making out invoice etc are irregularities were found.
Nanjing pharmaceutical subsidiary had "scam". , according to the nanjing medicine's announcement on February 14, 2017, the state food and drug supervision and administration bureau official website published "about source pharmaceutical co., LTD in fujian and so on 10 pharmaceutical wholesale enterprises results announcement 24 (2017). According to the above notice: "fujian southeast pharmaceutical co., LTD., to the enterprise financial documents show that huang transfer BuChaKuan, the enterprise provides the huang of henan accredit a power of attorney of the company for forgery. When the enterprises return drug issue a number of negative tax invoices content is not real, positive and negative output invoice the buyer and the goods do not agree names. The enterprise receiving staff not to verify the outbound order seal of suppliers, part of the outbound order seals do not agree with first battalion, the examination and approval materials. The company does not provide part of the cold chain drug transit temperature data. The temperature and humidity monitoring system in a number of data records with the background data backup, suspected of fraud there is temperature and humidity data." Fujian southeast for nanjing medical units. On February 20, 2017, fuzhou fujian southeast received market supervision and administration of the notice about confiscate the GSP certification.
In 2016, fudan after China subsidiary of receiving of falsely making out VAT invoice by tax regulators about 266 million yuan on the ticket, and this ticket is equivalent to fudan after China's net profit in the recent ten years.
"Companies are not willing to mergers and acquisitions, is afraid of holding related business companies after regulators found to historical issues." Shi Lichen said, integration and without adding in the field of pharmaceutical business. "Now a lot of medicine business enterprise value is very low, have do not have investment value". |
